{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"79.45","upperLimit":"93.89","value":"86.67"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"description":"EFS time is defined as time from treatment assignment to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto.","dispersionType":"90% Confidence Interval","groups":[{"description":"Eligible patients with MLL-G (germline, or non-rearranged)\n\nAsparaginase: Given IV, IM, or PO\n\nCyclophosphamide: Given IV\n\nCytarabine: Given IV or IT\n\nDaunorubicin Hydrochloride: Given IV\n\nDexamethasone: Given IV or PO\n\nEtoposide: Given IV\n\nFilgrastim: Given IV or SC\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLeucovorin Calcium: Given IV\n\nMercaptopurine: Given PO\n\nMethotrexate: Given IV, IT, or PO\n\nMethylprednisolone: Given IV\n\nPegaspargase: Given IM\n\nPharmacological Study: Correlative studies\n\nPrednisone: Given PO\n\nTherapeutic Hydrocortisone: Given IT\n\nVincristine Sulfate: Given IV","id":"OG000","title":"Arm A (Standard Risk MLL-G)"}],"paramType":"NUMBER","populationDescription":"All Eligible patients treated in Arm A (standard risk MLL-G).","reportingStatus":"POSTED","timeFrame":"From start of post-induction therapy for up to 10 years","title":"Percent Probability for Event-free Survival (EFS) for Patients on Arm A","type":"SECONDARY","unitOfMeasure":"percentage probability"}